Publication | Closed Access
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
166
Citations
33
References
2016
Year
Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaCancer BiologyCytarabine ResponseRadiation OncologyMolecular DiagnosticsCell BiologyCancer ResearchMyeloid Neoplasia
| Year | Citations | |
|---|---|---|
Page 1
Page 1